WEST
LAFAYETTE, Ind., April 28,
2024 /PRNewswire/ -- Nicholas
Baker, M.D., Director of Robotic Thoracic Surgery at the
University of Pittsburgh Medical Center
(UPMC) Passavant, presented key findings from independent research
at the 104th Annual Meeting of the American Association
for Thoracic Surgery (AATS) in Toronto,
Canada.
This is the first analysis of real-world experience for
intraoperative molecular imaging (IMI) with CYTALUX following the
phase 3 ELUCIDATE trial for cancer in the lung. The retrospective
review included 39 sublobar resection procedures at UPMC that used
CYTALUX to enhance the detection of cancer in the lung during
surgery.
"The real-world clinical outcome mirrors the experience reported
by the investigators in the phase 3 trial and reinforces that this
approach improves our ability to detect primary and metastatic
pulmonary lesions," said Dr. Baker.
The clinical outcome demonstrated an improvement in lung nodule
localization, occult lesion identification and resection margin
assessment, with CYTALUX aiding in the detection of primary lung
cancer and metastatic lesions. The technology enabled the
identification of 85.7% of primary lung cancer lesions compared to
67.9% identified using standard localization techniques without
IMI. In addition, CYTALUX proved instrumental in identifying occult
lesions intraoperatively that otherwise had no prior imaging
correlates, revealing at least one additional malignancy in 18% of
cases.
"This technology represents a significant advancement over the
way we have traditionally managed lung cancer in the operating
room," said Ryan Levy, M.D., Chief of Thoracic Surgery at UPMC
and co-author of the analysis shared at AATS. "The clinically
proven ability to specifically target and visually detect occult
and difficult-to-find lung lesions has dramatic implications for
the way we approach and manage patients with lung cancer. I
anticipate some of the biggest impact will be in patients with
multifocal ground glass type cancers."
CYTALUX was first approved as an adjunct for intraoperative
identification of malignant lesions for use in adult patients with
ovarian cancer in November 2021 and
for adult patients with lung cancer in December 2022. CYTALUX is the first targeted
molecular imaging agent that illuminates ovarian and lung cancer
intraoperatively, enabling the detection of more cancer for
removal. CYTALUX, administered by standard IV in as little as one
hour before surgery, binds to folate receptors that are
overexpressed in certain cancers1,2 and illuminates
intraoperatively under near-infrared light.
For more information about CYTALUX, visit
CYTALUX.com.
About On Target Laboratories, Inc.
On Target Laboratories discovers and develops targeted
intraoperative molecular imaging agents to illuminate cancer during
surgery. Their molecular imaging technology, based on the
pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for
Drug Discovery and the Ralph C. Corley Distinguished Professor of
Chemistry, is comprised of a near-infrared dye and a targeting
molecule, or ligand, that binds to receptors overexpressed on
cancer cells. The imaging agents illuminate the cancerous tissue,
which may enable surgeons to detect more cancer that otherwise may
have been left behind.
CYTALUX, the company's first product, received FDA approval of a
New Drug Application for ovarian cancer in November
2021 and a supplemental New Drug Application for lung cancer
in December 2022. CYTALUX targets the folate receptors
commonly found on many cancers, binds to the cancerous tissue, and
illuminates under near-infrared light. A single dose of the agent
is administered via intravenous infusion prior to surgery and
assists surgeons in visually identifying additional cancerous
tissue to be removed during the operation. For more information
visit www.ontargetlabs.com and www.cytalux.com.
____________________
|
1 Predina JD, Newton AD,
Connolly C, Dunbar A, Baldassari M, Deshpande C, Cantu E 3rd,
Stadanlick J, Kularatne SA, Low PS, Singhal S. Identification of a
Folate Receptor-Targeted Near-Infrared Molecular Contrast Agent to
Localize Pulmonary Adenocarcinomas. Mol Ther. 2018 Feb
7;26(2):390-403. doi: 10.1016/j.ymthe.2017.10.016. Epub 2017 Oct
26. PMID: 29241970; PMCID: PMC5835020.
|
2
Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a
tumor target in epithelial ovarian cancer. Gynecologic Oncology.
2008;108(3):619-626.
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cytalux-real-world-experience-presented-at-the-american-association-for-thoracic-surgery-104th-annual-meeting-302129307.html
SOURCE On Target Laboratories, Inc.